Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle
Phase II Study to Investigate the Efficacy and Safety of BioCart™II in the Treatment of Symptomatic Cartilage Defects of the Femoral Condyle in Comparison With Microfracture
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ramat Gan, Israel, 52662
- Sheba Medical Center Tel Hashomer
-
Tel Aviv, Israel, 64239
- Tel Aviv Sourasky Medical Center
-
Zerifin, Israel, 70300
- Assaf Harofeh Medical Center
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85712
- Tucson Orthopaedic Institute
-
-
Georgia
-
Savannah, Georgia, United States, 31405
- Southeastern Orthopedic Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
- Sinai Hospital of Baltimore
-
-
New York
-
New York, New York, United States, 10029-6754
- Mount Sinai Medical Center
-
-
Pennsylvania
-
Altoona, Pennsylvania, United States, 16602
- University Orthopedics Center
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 16 to 60 years
- Femoral condyle lesion (medial, lateral or trochlea)
- Single contained lesion
- Symptomatic (moderate to severe pain on VAS)
- Caused by trauma or OCD
- Depth of lesion up to 6 mm
- Size of lesion 1.5-7.5 cm2
- No general bone or cartilage pathology
- No limb mal-alignment (long leg standing X-ray)
- Mechanically stable knee
- Accompanying pathology menisectomy up to 50%
- Willing and able to comply with protocol and undergo vigorous rehabilitation
- Signed informed consent
Exclusion Criteria:
- Multiple cartilage lesions of the knee, other location than femoral condyle (medial, lateral or trochlear), deeper than 6 mm, smaller than 1.5cm2 or greater than 7.5cm2, mild symptoms, caused by reason other than trauma or OCD, unstable knee, accompanying pathology other than 50% menisectomy.
- Hyaluronic acid knee injections in the past 3 months,
- History of chronic bone or cartilage disorder, bilateral knee pain and/or cartilage lesion
- History of any neoplastic disease, or chemotherapy treatment
- Chronic steroid intake, chronic pain medication use for conditions other than the involved knee, use of blood thinners (during the past 10 days prior to enrollment)
- History of allergy or atopic disease, sensitivity to blood products
- Evidence of any significant systemic disease, known coagulopathies or acute injury that might compromise the patient's welfare
- Pregnant or lactating women
- Substance or alcohol abuse
- Microfracture to the affected knee within the previous 2 years
- Participation in concurrent trials
- Participation in previous trials within 3 months
- Malignancy
- Taking specific drugs for osteoarthritis, such as chondroitin sulfate, diacerein, n-glucosamine, piaseledine, or capsaicin within 2 weeks of the baseline visit
- Chronic use of anticoagulants
- Uncontrolled diabetes
- Active joint infection
- Other unstable cardiac and pulmonary disorder
- Liver enzymes (SGOT, SGPT, alkaline phosphatase) of more then two times the upper limit of normal or any other results that in the clinical investigator's mind is important clinically
- Clinical and/or radiographic disease in the indexed affected joint that includes:
- Osteoarthritis or avascular necrosis
- Rheumatoid arthritis or a history of septic or reactive arthritis
- Gout or a history of gout or pseudogout in the affected knee
- Osteochondritis dissecans of the knee with significant bone loss
- Bipolar articular cartilage involvement (or kissing lesions) of the ipsilateral compartment (i.e >than ICRS grade 2 on the opposing articular surface)
- Associated damage to the underlying subchondral bone requiring an osteochondral graft
- History of secondary arthropathies (i.e. sickle cell disease, Hemochromatosis, or autoimmune disease)
- Receiving prescription pain medication other than NSAIDs or acetaminophen for conditions unrelated to the index knee conditions
- BMI >40 kg/m2
- Unable to undergo MRI
- Any reasons making the patient a poor candidate in the eyes of the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: A
BioCart™II treatment
|
A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation.
Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium.
Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
Other Names:
|
|
Active Comparator: B
Microfracture procedure
|
MF procedure will be carried out according to accepted practice.
After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl.
The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation.
With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn.
This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement in the Lysholm joint function score of subjects in the BioCart™II study group compared with the MF study group
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improvement in clinical function post implantation/surgery compared to baseline in the study group and compared with the control group, of the following:
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
|
IKDC knee score
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
|
KOOS questionnaire
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
|
ICRS functional status
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
|
VAS pain score
Time Frame: 12 months with optional follow up to 5 years
|
12 months with optional follow up to 5 years
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Avner Yayon, PhD MD, ProChon Biotech Ltd
Publications and helpful links
General Publications
- Nehrer S, Chiari C, Domayer S, Barkay H, Yayon A. Results of chondrocyte implantation with a fibrin-hyaluronan matrix: a preliminary study. Clin Orthop Relat Res. 2008 Aug;466(8):1849-55. doi: 10.1007/s11999-008-0322-4. Epub 2008 Jun 5.
- Domayer SE, Welsch GH, Nehrer S, Chiari C, Dorotka R, Szomolanyi P, Mamisch TC, Yayon A, Trattnig S. T2 mapping and dGEMRIC after autologous chondrocyte implantation with a fibrin-based scaffold in the knee: preliminary results. Eur J Radiol. 2010 Mar;73(3):636-42. doi: 10.1016/j.ejrad.2008.12.006. Epub 2009 Jan 20.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- BioCart™II 005-06
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.